Latest Safety News

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

Imricor Medical Systems has completed the world’s first Pulsed Field Ablation procedure under real-time MRI guidance, marking a breakthrough in cardiac ablation technology. This pre-clinical success validates their Vision-MR platform’s adaptability and sets the stage for safer, radiation-free heart treatments.

Podium Minerals has achieved a metallurgical breakthrough at its Parks Reef project, delivering an 80% recovery of key metals and a 50-fold concentrate grade upgrade. The company is advancing a A$12 million capital raise to accelerate development amid soaring platinum and palladium prices.

Brazilian Critical Minerals has achieved a major environmental milestone at its Ema Rare Earth Elements project, successfully restoring clay chemistry post in-situ recovery trials. This breakthrough supports regulatory approvals and moves the project closer to production.

Aquirian Limited has secured a $2.3 million strategic placement with Topgroup and signed a non-binding Memorandum of Understanding to form Drillforce WA, a 50 – 50 joint venture combining their drilling and blasting expertise.

Infini Resources is fast-tracking exploration at its Reynolds and Reitenbach Lake uranium projects following the identification of visible uraninite and multiple radiometric anomalies, signaling promising potential in Saskatchewan’s Athabasca Basin.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows promising response rates in first line non-small cell lung cancer, especially in patients with low or no PD-L1 expression.

Immutep Limited’s Phase II trial of eftilagimod alfa combined with radiotherapy and KEYTRUDA in soft tissue sarcoma patients has exceeded its primary endpoint, showing a 51.5% median tumor hyalinization rate, more than triple the historical standard. These promising results, presented at ESMO 2025, suggest a potential breakthrough in a challenging cancer indication.

Saunders International has landed a $19.8 million contract to build 11 tanks at a gold processing facility, reinforcing its foothold in the resources sector and promising revenue growth over the next two years.

Etherstack's subsidiary has won a significant £14.2 million contract to supply critical software for the UK's Emergency Services Network, marking a major milestone in mission-critical communications.